徳島大学 教育・研究者情報データベース(EDB)

Education and Research Database (EDB), Tokushima University

徳島大学ウェブサイトへのリンク

著作: [福本 誠二]/Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale?/[Frontiers in Endocrinology]

ヘルプを読む

「著作」(著作(著書,論文,レター,国際会議など))は,研究業績にかかる著作(著書,論文,レター,国際会議など)を登録するテーブルです. (この情報が属するテーブルの詳細な定義を見る)

  • 項目名の部分にマウスカーソルを置いて少し待つと,項目の簡単な説明がツールチップ表示されます.

この情報をEDB閲覧画面で開く

EID
337065
EOID
939654
Map
0
LastModified
2019年3月2日(土) 20:41:00
Operator
[ADMIN]
Avail
TRUE
Censor
0
Owner
福本 誠二
Read
継承
Write
継承
Delete
継承
種別 必須 総説·解説
言語 必須 英語
招待 推奨
審査 推奨
カテゴリ 推奨
共著種別 推奨
学究種別 推奨
組織 推奨
著者 必須
  1. 福本 誠二([徳島大学.先端酵素学研究所.基幹研究部門])
    役割 任意
    貢献度 任意
    学籍番号 推奨
題名 必須

(英) Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale?

副題 任意
要約 任意

(英) Fibroblast growth factor 23 (FGF23) is a phosphotropic hormone mainly produced by bone. FGF23 reduces serum phosphate by suppressing intestinal phosphate absorption through reducing 1,25-dihydroxyvitamin D and proximal tubular phosphate reabsorption. Excessive actions of FG23 result in several kinds of hypophosphatemic rickets/osteomalacia including X-linked hypophosphatemic rickets (XLH) and tumor-induced osteomalacia. While neutral phosphate and active vitamin D are standard therapies for child patients with XLH, these medications have several limitations both in their effects and adverse events. Several approaches that inhibit FGF23 actions including anti-FGF23 antibodies and inhibitors of FGF signaling have been shown to improve phenotypes of model mice for FG23-related hypophosphatemic diseases. In addition, clinical trials indicated that a humanized anti-FGF23 antibody increased serum phosphate and improved quality of life in patients with XLH. Furthermore, circulatory FGF23 is high in patients with chronic kidney disease (CKD). Many epidemiological studies indicated the association between high FGF23 levels and various adverse events especially in patients with CKD. However, it is not known whether the inhibition of FGF23 activities in patients with CKD is beneficial for these patients. In this review, recent findings concerning the modulation of FGF23 activities are discussed.

キーワード 推奨
発行所 推奨
誌名 必須 Frontiers in Endocrinology(Frontiers Research Foundation)
(eISSN: 1664-2392)
ISSN 任意 1664-2392
ISSN: 1664-2392 (eISSN: 1664-2392)
Title: Frontiers in endocrinology
Title(ISO): Front Endocrinol (Lausanne)
Publisher: Frontiers Media S.A.
 (NLM Catalog  (Scopus  (CrossRef (Scopus information is found. [need login])
必須 9
必須
必須 48 48
都市 任意
年月日 必須 2018年 2月 20日
URL 任意
DOI 任意 10.3389/fendo.2018.00048    (→Scopusで検索)
PMID 任意 29515522    (→Scopusで検索)
NAID 任意
WOS 任意
Scopus 任意
機関リポジトリ 112959
評価値 任意
被引用数 任意
指導教員 推奨
備考 任意
  1. (英) Article.ELocationID: 10.3389/fendo.2018.00048

  2. (英) Article.PublicationTypeList.PublicationType: Journal Article

  3. (英) Article.PublicationTypeList.PublicationType: Review

  4. (英) KeywordList.Keyword: antibody

  5. (英) KeywordList.Keyword: chronic kidney disease-mineral and bone disorder (CKD-MBD)

  6. (英) KeywordList.Keyword: hypophosphatemia

  7. (英) KeywordList.Keyword: osteomalacia

  8. (英) KeywordList.Keyword: rickets